| Species |
Human |
| Protein Construction |
Betacellulin (Asp32-Tyr111)
Accession # P35070 |
|
| Purity |
> 95% as analyzed by SDS-PAGE |
| Endotoxin Level |
< 0.2 EU/μg of protein by gel clotting method |
| Biological Activity |
ED50 < 4.0 pg/ml, measured in a cell proliferation assay using 3T3 cells. |
| Expression System |
HEK 293 |
| Apparent Molecular Weight |
15~18 kDa, on SDS-PAGE under reducing conditions. |
| Formulation |
Lyophilized after extensive dialysis against PBS. |
| Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH₂O or PBS up to 100 μg/ml. |
| Storage & Stability |
Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles. |
| Target Background |
Betacellulin (BTC) is a member of the EGF family of growth factors that also includes EGF, TGF-α, Amphiregulin, HB-EGF, Epiregulin, Tomoregulin, Heregulin and Neuregulins. Mature human BTC protein exhibits 80% amino acidsimilarity with mouse BTC protein. BTC is expressed in most tissues including kidney, uterus, liver and pancreas. It is also present in body fluids, including serum, milk, and colostrum. It is synthesized primarily as a transmembrane precursor, which is then processed to a mature molecule by proteolytic events. BTC signals through the EGF receptor. |
| Synonyms |
BTC |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
